ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sutezolid

Also written as “PNU-100480”, “BIA 5-1058 and Furosemide” and “Treatment C”.

Its studies are mostly in Tuberculosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, Type 2, led by 3 companies.

Drug pagePNU-100480: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Oct 19, 20105 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sequellaits history only30 open or runningphase 2since Oct 19, 2010Mar 27, 2009none ahead
AJU Pharmits history only10 open or runningphase 1since Jul 12, 2021Jul 12, 2021none ahead
Bial - Portela C10 open or runningphase 1since Sep 8, 2025Sep 8, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bial - Portela C only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2025First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT07173738 · 44 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“70S ribosome inhibitor”ChEMBL 37, by rule

Studies

The one study Bial - Portela C leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07173738Pulmonary Arterial Hypertension · United Kingdom1CompletedSep 7, 201844

How it is read

Names in the registry

  • “PNU-100480”, 23 entries
  • “BIA 5-1058 and Furosemide”, 1 entry
  • “Treatment C”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.